feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Orphazyme: First patient dosed in ALS Phase III study
Research Note
2018-08-10
19:30
Orphazyme announced late today that the first patient has been dosed in their Phase III ALS study with arimoclomol.
MS
Mathias Spinnars
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans